The drug semaglutide, typically prescribed for treatment of Type 2 diabetes, was used in a phase 3 clinical trial as a treatment for obesity with very promising results. Northwestern's Robert Kushner, MD, led this study, recently published in the New England Journal of Medicine and shares the results.